Call Options

9 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$1.0 - $58.8 $9,200 - $540,960
-9,200 Reduced 20.72%
35,200 $51,000
Q3 2022

Nov 14, 2022

SELL
$1.32 - $58.0 $114,312 - $5.02 Million
-86,600 Reduced 66.11%
44,400 $63,000
Q2 2022

Aug 15, 2022

SELL
$1.28 - $2.31 $119,552 - $215,754
-93,400 Reduced 41.62%
131,000 $182,000
Q1 2022

May 16, 2022

BUY
$1.82 - $3.5 $354,900 - $682,500
195,000 Added 663.27%
224,400 $507,000
Q2 2021

Aug 11, 2021

SELL
$3.11 - $4.87 $45,095 - $70,615
-14,500 Reduced 33.03%
29,400 $98,000
Q1 2021

May 17, 2021

SELL
$3.66 - $7.67 $719,922 - $1.51 Million
-196,700 Reduced 81.75%
43,900 $189,000
Q4 2020

Feb 16, 2021

BUY
$3.03 - $5.51 $451,167 - $820,439
148,900 Added 162.38%
240,600 $998,000
Q3 2020

Nov 16, 2020

BUY
$2.9 - $4.29 $134,270 - $198,627
46,300 Added 101.98%
91,700 $308,000
Q1 2020

May 15, 2020

BUY
$0.28 - $6.23 $12,712 - $282,842
45,400 New
45,400 $110,000

Others Institutions Holding GNPX

About Genprex, Inc.


  • Ticker GNPX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,020,300
  • Market Cap $76.8M
  • Description
  • Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...
More about GNPX
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.